Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RBM18 is an RNA-binding protein containing a canonical RNA recognition motif (RRM) domain, predominantly located in the cytosol, nucleoplasm, and intercellular bridge. Its primary function is predicted to be RNA binding and nucleotide binding. It is thought to participate in the regulation of RNA metabolic processes typical for the RRM family, including modulation of splicing, RNA stabilization, and transport. While genetic association studies link RBM18 to some diseases (e.g., prostatic cyst, Moyamoya disease 1), there is currently minimal evidence supporting a direct pathogenic or therapeutic role. RBM18 is not classified as a therapeutic target and lacks known drug interactions or mechanisms of action in the context of drug development. The gene is highly conserved and has orthologs across species, but its precise biological and clinical significance remains under-characterized.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA binding motif protein 18 (RBM18).